Frequently Asked Questions for the Illuminating the Druggable Genome Implementation Phase
Updated 4/16/2020
We appreciate your interest in the Illuminating the Druggable Genome Program Request for Application (RFA-RM-20-019) and hope that you and your team will choose to submit an application. In order to maximize your chances of success, we would like to provide some guidance that may be helpful as you put the finishing touches on your application
- Illuminating the Druggable Genome Overview
- Opportunity Pool R03 Objectives
- Application Budget and Submission Requirements
2. What is the goal of the Illuminating the Druggable Genome (IDG) Program?
3. What are the experimental approaches being taken in the IDG Program?
1. What kind of research falls under this FOA?
3. Can I propose to study proteins that are not on the list in the FOA?
5. Who is the NIH contact for RFA-RM-20-019 and should I contact them before applying to this FOA?
Application Budget and Submission Requirements
2. Can an institution/research team submit more than one application to the RFA?
3. Do I need to send a letter of intent?
4. Is collaboration with IDG investigators required to submit an application?
5. Can work be performed outside the US?
6. What are the requirements for data and resource sharing for this FOA?
7. How will applications submitted to RFA-RM-20-019 be reviewed?
This page last reviewed on October 20, 2020